ArticleMMWR. Morbidity and mortality weekly report2024
COVID-19 Vaccination Coverage - World Health Organization African Region, 2021-2023.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- COVID- 19 vaccine uptake and its determinants in Cameroon: a systematic review and meta-analysis (2021-2024).BMC infectious diseases · 2025Pooled it
- Association of gross domestic product with equitable access to childhood vaccines in 195 countries: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Acceptance of the COVID-19 Booster Vaccine Amid the Omicron JN.1 Surge in Southern Bangladesh: A Comparative Analysis of Rural-Urban Disparities.Risk analysis : an official publication of the Society for Risk Analysis · 2026Observational
- Cultural-Social-Economic Background and Community Engagement Impacting COVID-19 Vaccination Uptake Among Pregnant and Lactating Refugee Women.Journal of immigrant and minority health · 2026Article
- Article
- Genomic Surveillance of SARS-CoV-2 in Senegal (2020-2024): Variant Turnover, Omicron Introductions, and Interregional Spread.Influenza and other respiratory viruses · 2026Article
- Article
- Longitudinal Antibody Dynamics Following SARS-CoV-2 Viral-Vectored and mRNA Booster Vaccination in Ghanaian Adults.Vaccines · 2026Article
- Health beliefs model and vaccine acceptance: insights from the COVID-19 pandemic among non-medical personnel in Mwanza, Tanzania.BMC public health · 2026Article
- Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa.BMC medicine · 2026Article
- COVID-19 knowledge, attitudes, and practices among people vulnerable to HIV in Uganda: A cross-sectional cohort analysis.PloS one · 2026Article
- Integrated surveillance in Kilifi reveals continued SARS-CoV-2 circulation and immune escape of emerging JN.1 sublineages post-pandemic.Frontiers in cellular and infection microbiology · 2026Article
- Scope and Spatio-Temporal Patterns of Workplace Vaccination Mandates During the COVID-19 Pandemic.International journal of environmental research and public health · 2025Article
- Seroprevalence and molecular detection of SARS-CoV-2 among apparently healthy healthcare workers and patients in a Nigerian tertiary hospital.BMC infectious diseases · 2025Article
- Review
- Completion of Multidose COVID-19 Vaccination Among Adolescents and Adults in Urban Informal Settlements in Nairobi, Kenya.The American journal of tropical medicine and hygiene · 2025Article
- Overcoming Vaccine Inequities and Research Gaps in Africa: Challenges and Opportunities Identified During the COVID-19 Pandemic.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Genome diversity of SARS-CoV-2 lineages associated with vaccination breakthrough infections in Addis Ababa, Ethiopia.BMC infectious diseases · 2025Article
- Early 2022 breakthrough infection sera from India target the conserved cryptic class 5 epitope to counteract immune escape by SARS-CoV-2 variants.Journal of virology · 2025Article
- Global Status of Adult Immunization Post COVID-19 Pandemic.Vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the availability of authorized COVID-19 vaccines in early 2021, vaccination became an effective tool to reduce COVID-19-associated morbidity and mortality. Initially, the World Health Organization (WHO) set an ambitious target to vaccinate 70% of the global population by mid-2022. However, in July 2022, WHO recommended that all countries, including those in the African Region, prioritize COVID-19 vaccination of high-risk groups, including older adults and health care workers, to have the greatest impact on morbidity and mortality. As of December 31, 2023, approximately 860 million doses of COVID-19 vaccine had been delivered to countries in the African Region, and 646 million doses had been administered. Cumulatively, 38% of the African Region's population had received ≥1 dose, 32% had completed a primary series, and 21% had received ≥1 booster dose. Cumulative total population coverage with ≥1 dose ranged by country from 0.3% to 89%. Coverage with the primary series among older age groups was 52% (range among countries = 15%-96%); primary series coverage among health care workers was 48% (range = 13%-99%). Although the COVID-19 public health emergency of international concern was declared over in May 2023, current WHO recommendations reinforce the need to vaccinate priority populations at highest risk for severe COVID-19 disease and death and build more sustainable programs by integrating COVID-19 vaccination into primary health care, strengthening immunization across the life course, and improving pandemic preparedness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.